Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles
Stretch Mark

Klobuchar, Kohl, Franken Call For Value-Index Approach To Combat Medicare Costs
Today, U.S. Senators Amy Klobuchar (D-MN), Herb Kohl (D-WI) and Al Franken (D-MN) introduced legislation to reform the Medicare payment system to reward hospitals for quality, efficient care. The Medicare Payment Fairness Act of 2009 would reform Medicare by paying hospitals for the quality, not quantity, of care. These changes would reduce the regional differences in Medicare spending by shifting the nation to a coordinated, integrated delivery system - like Minnesota, Wisconsin, and other states. Studies have shown that more integrated care could save taxpayers an additional $100 billion a year.
generic viagra online
A Combination Of Micronutrients Is Beneficial In Reducing The Incidence Of Prostate Cancer And Increasing Survival In The Lady Transgenic Model
UroToday.com - Dietary micronutrients are a common component of people"s diet as they seek to prevent cancer and other diseases. Micronutrients protect against cellular oxidative damage by neutralizing oxygen free radicals. In the May 2009 issue of Cancer Prevention Research, Dr. VasundaraVenkateswaran and associates tested the effects and timing of the micronutrients vitamin E (E), selenium (S), and lycopene (L) on the development of prostate cancer (CaP) in the Lady transgenic model.
News of the day
American Career College's Ontario Campus Approved To Offer Respiratory Therapy Program
American Career College has gained approval to offer a Respiratory Therapy (RT) program at its Ontario campus, where the program"s initial class will commence on July 20, 2009. Currently, American Career College offers an RT program at its Orange County campus in Anaheim.
Mental Health

New Therapy Found To Prevent Heart Failure

A landmark study has successfully demonstrated a 29 percent reduction in heart failure or death in patients with heart disease who received an implanted cardiac resynchronization therapy device with defibrillator (CRT-D) versus patients who received only an implanted cardiac defibrillator (ICD-only). MADIT-CRT (Multicenter Automatic Defibrillator Implantation Trial with Cardiac Resynchronization Therapy) is a clinical trial that enrolled more than 1,800 patients in the United States, Canada and Europe and followed the patients for up to 41/2 years. The results of the trial were released today by the University of Rochester Medical Center and Boston Scientific, the study"s sponsor. The MADIT-CRT Executive Committee stopped the trial on June 22, 2009, when the trial achieved its primary end point - significant reduction in heart failure or death with CRT-D versus ICD-only. Cardiologist Arthur Moss, M.D., professor of Medicine at the University of Rochester Medical Center, led the MADIT-CRT trial. A prior study (MADIT-II) led by Moss and associates in 2002 showed the ICD was effective in reducing mortality. The current MADIT-CRT study sought to determine if CRT-D could reduce the risk of mortality and heart failure, which affects 5.7 million Americans, and the results were very positive. Patients with heart disease have a risk of arrhythmias and heart failure. The new generation of cardiac resynchronization therapy defibrillators (CRT-Ds) was designed to stop dangerous, life-threatening heart rhythms and improve the heart"s contraction, thereby enabling the device to improve survival and prevent heart failure. CRT-Ds are approved for use in patients with severe heart failure (New York Heart Association class III/IV), where they have been shown to reduce heart failure symptoms. The findings from the current study indicate that CRT-D therapy improves cardiac function and prevents the development of heart failure in patients who have not previously experienced heart failure. "Now we can prevent sudden cardiac death and inhibit the development of heart failure, thus improving survival and outcome in patients with heart disease," Moss said. "There is a very large population of patients with heart disease who will benefit from this combined therapy." Prior to 2008, Moss received honoraria from Boston Scientific for talks at scientific programs. He holds no stock in any device company, and since Dec. 1, 2008, has received no honoraria from Boston Scientific for any professional activity. University of Rochester Medical Center


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009